Obinutuzumab in patients with Sjogrens disease immunised against rituximab

Patients treated with rituximab (RTX) may develop antidrug antibodies (ADAb) leading to inefficacy and infusion reactions,1 more frequently in systemic autoimmune diseases (sAID) than in rheumatoid arthritis.2 In those immunised patients, targeting B-cells with another anti-CD20 molecule is an option. Obinutuzumab (OBZ) is another anti-CD20 antibody used in lymphoproliferative malignancies.3 Few studies reported its efficacy and safety in patients with sAID,4–6 and none reported documented anti-RTX immunisation. Thus, it remains unknown if OBZ can be safe and efficient in patients with ADAb to RTX. This retrospective study included consecutive patients with Sjogren’s disease (SjD) and systemic complications, seen between 2019 and 2023 in our tertiary centre, treated with RTX and having developed anti-RTX ADAb. Safety was collected based on patients records that describe all the hospitalisations occurring during the follow-up. Response to OBZ was determined by the...
Source: Annals of the Rheumatic Diseases - Category: Rheumatology Authors: Tags: ARD Letter Source Type: research